Virtual Library
Start Your Search
S. Yang
Author of
-
+
P3.02b - Poster Session with Presenters Present (ID 494)
- Event: WCLC 2016
- Type: Poster Presenters Present
- Track: Advanced NSCLC
- Presentations: 1
- Moderators:
- Coordinates: 12/07/2016, 14:30 - 15:45, Hall B (Poster Area)
-
+
P3.02b-085 - The Combination Therapy of S-1 and the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors beyond Progressive Disease (ID 4078)
14:30 - 14:30 | Author(s): S. Yang
- Abstract
Background:
There is no optimal therapy established for those who have progressed with the Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI). And some preclinical study indicated that the addition of S-1 to EGFR-TKIs might overcome EGFR-TKI resistance. This study was conducted to investigate the efficacy and safety of the combination therapy of S-1 and EGFR-TKIs for patients failed the previous EGFR-TKI treatments.
Methods:
All patients who received the combination therapy of S-1 and EGFR-TKIs beyond progressive disease with EGFR-TKI monotherapy in the Cancer Hospital, the Chinese Academy of Medical Sciences between 2013 and 2016 with complete records were enrolled in this study. The primary endpoint was progression-free survival (PFS), while the disese control rate and safty were secondary endpoints. Multivariate analysis for survival was conducted including age, gender, initiation of EGFR-TKI, the choice of EGFR-TKI, the best efficacy while using EGFR monotherapy and the choice of S-1 and EGFR-TKI.
Results:
A total of 43 non-small-lung cancer (NSCLC) patients who met the inclusion criteria were enrolled in this study. The median PFS for all patients was 5.47 months (95% confidence interval [CI] 3.444-7.489). The disease control rate is 67.4%(29/43). There was no grade 4 toxicity and no grade 3 hematologic toxicity in this study. One patient has grade 3 elevated total serum bilirubin. Cox analysis showed that the combination treatment of S-1 and erlotinib was associated with decreased PFS comparing the gefitinib (hazards ratio[HR] 8.401, 95% CI 2.781-25.379, p<0.001). Besides, male (HR 0.389, 95%CI 0.162-0.934, p=0.035) and patients with SD (HR 0.303, 95%CI 0.124-0.471, p=0.009) or PD (HR 0.031, 95%CI 0.002-0.450, p=0.011) in the monotherapy of EGFR-TKIs were associated with increased PFS.
Conclusion:
The combination treatment of S-1 and EGFR-TKIs is effective and well-tolerated treatment for those failed prior EGFR-TKI. This strategy is promising to overcome EGFR-TKI resistance in NSCLC. A prospective study will be needed to confirm our studys.
